MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

Kodu・Aktsiate loetelu・Savara Inc

Savara Inc

Suletud

SektorTervishoid

6 -6.54

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

6.09

Põhinäitajad
By Trading Economics
Sissetulek	840K -30M
Aktsiakasum	-0.14
Töötajad	59
EBITDA	841K -29M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+66.11% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. märts 2026

Turustatistika
By TradingEconomics
Turukapital	379M 1.2B
Eelmine avamishind	12.54
Eelmine sulgemishind	6

Uudiste sentiment

By Acuity

42%

58%

98 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

2.76 / 2.84 Toetus ja vastupanu

Savara Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. jaan 2026, 18:41 UTC

Tulu

SLB Readies Rapid Expansion in Venezuela -- 2nd Update

24. jaan 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24. jaan 2026, 09:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

24. jaan 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. jaan 2026, 09:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

24. jaan 2026, 06:18 UTC

Omandamised, ülevõtmised, äriostud

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

23. jaan 2026, 22:30 UTC

Market Talk

Global Equities Roundup: Market Talk

23. jaan 2026, 22:30 UTC

Market Talk

Trump Seen Using Canada's EV Deal With China to Extract Concessions -- Market Talk

23. jaan 2026, 22:03 UTC

Tulu

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23. jaan 2026, 21:52 UTC

Tulu

Omandamised, ülevõtmised, äriostud

GE Aerospace's Earnings Worried the Market. What CEO Larry Culp Says. -- Barrons.com

23. jaan 2026, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

23. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. jaan 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

23. jaan 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

23. jaan 2026, 21:39 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 5th Update

23. jaan 2026, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Eaton Completes Acquisition Of Ultra PCS Limited, Expanding Capabilities And Solutions For Next-generation Aerospace And Defense Markets >ETN

23. jaan 2026, 21:12 UTC

Tulu

CSX Stock Rises After Earnings Miss Estimates. It's the Outlook. -- Barrons.com

23. jaan 2026, 20:31 UTC

Tulu

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23. jaan 2026, 20:12 UTC

Market Talk

Oil Futures Rebound on Iran, Russia-Ukraine Risk -- Market Talk

23. jaan 2026, 20:07 UTC

Market Talk

U.S. Natural Gas Posts Record Weekly Gain on Winter Storm -- Market Talk

23. jaan 2026, 19:36 UTC

Market Talk

Dollar Weakens Against Yen Amid Intervention Chatter -- Market Talk

23. jaan 2026, 19:30 UTC

Market Talk

Tulu

Intel's Stock Has Limited Catalysts Ahead, Analysts Say -- Market Talk

23. jaan 2026, 19:18 UTC

Market Talk

Gold and Silver Step Up to More Records -- Market Talk

23. jaan 2026, 19:15 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 4th Update

23. jaan 2026, 18:53 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 411 -- Market Talk

23. jaan 2026, 18:21 UTC

Tulu

Week's Best: Schwab's Assets and Profits Keep Climbing -- Barrons.com

23. jaan 2026, 18:19 UTC

Market Talk

Intel Seen as Increasingly Confident on Demand -- Market Talk

23. jaan 2026, 17:59 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 3rd Update

23. jaan 2026, 17:57 UTC

Market Talk

Intel Could Sign Deals With Big Tech Players for 14A -- Market Talk

23. jaan 2026, 17:57 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Savara Inc Prognoos

Hinnasiht

By TipRanks

66.11% tõus

12 kuu keskmine prognoos

Keskmine 10 USD 66.11%

Kõrge 11 USD

Madal 9 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Savara Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Savara Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.76 / 2.84Toetus ja vastupanu

The bullish and bearish events are balanced.

All events are bullish.

Bullish events outweigh bearish events.

Sentiment

By Acuity

98 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.